Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Columbia researchers have learned why some glioblastomas--the most common type of brain cancer--respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.
Around a glioblastoma, a very aggressive brain tumor, cells of the human immune system start helping the tumor instead of attacking it. To do research on what happens in the interaction of these cells, scientists of the University of Twente now created a 3D-bioprinted mini model of the brain.
A breakthrough for brain tumor drug development and personalized medicine published today in Nature Scientific Reports.
Following a California Institute for Regenerative Medicine Independent Citizens Oversight Committee meeting held last week, University of California, Irvine researchers learned they will receive $6 million in funding to support the continued development of a promising new treatment for Huntington's disease
A study led by investigators from Massachusetts General Hospital (MGH) and the University of Cyprus reveals details of a way the dangerous brain tumors called glioblastomas resist the effects of antiangiogenic drugs designed to cut off their blood supply.
Corning Incorporated will showcase advanced 3D cell culture technologies and workflow solutions, and including those for high throughput screening and ADME/toxicology at SLAS 2019.
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
The Damon Runyon Cancer Research Foundation announced that nine scientists with novel approaches to fighting cancer have been named 2019 recipients of the Damon Runyon-Rachleff Innovation Award.
A Massachusetts General Hospital-led research team has demonstrated, for the first time, how solid stress - the physical forces exerted by the solid components of a tumor - impacts the tissue surrounding brain tumors and contributes to resulting neurological dysfunction and neuronal cell death.
Scientists have discovered molecular signatures that reveal why women are more likely to develop and die from the brain cancer, glioblastoma.
An interview with Dr. Tim Steppe, discussing the latest advances in the CLARITY technique and his top tips for scientists using this method in their research.
The European Organisation for Research and Treatment of Cancer Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors.
How does cancer spread? While studying human brain tumor cells, a team of scientists at the Research Institute of the McGill University Health Centre found some answers to this crucial, yet so far unanswered question.
Glioblastoma, a deadly brain cancer that has grabbed headlines for claiming the lives of Sens. Edward Kennedy and John McCain, could be "tricked" into sparing more of its victims.
Merck, the vibrant science and technology company, recognized three graduate students who have demonstrated innovation in life science at an awards ceremony at the company’s global headquarters in Darmstadt, Germany recently.
The tissues in our bodies largely are made of fluid. It moves around cells and is essential to normal body function.
Scientists at the Virginia Tech Carilion Research Institute have solved a 125-year-old mystery of the brain, and, in the process, uncovered a potential treatment for acquired epilepsy.
A new study by UT Health San Antonio researchers found that a molecule thousands of times smaller than a gene is able to kill medulloblastoma, the most common childhood brain cancer.
Glioblastoma is a serious and incurable brain cancer. Patients receiving this diagnosis typically have 11-20 months to live. One of the main difficulties in treating this cancer is that its cells quickly build up a resistance to chemotherapy.